Guideline Resources
COVID-19 Drug Therapy Trial Updates
Key Points
Updated 10/23/20. Remdesivir is FDA-approved to treat COVID-19. Many other drugs have reported in vitro activity or theoretical basis for antiviral activity. Some agents have encouraging evidence demonstrating clinical efficacy. All trial links in this resource lead to pre-filtered search results (by drug) at

Which aspects of this resource are most valuable to you (trial results, expanded access details, links to clinical trials)? Share your feedback with epocrates.
Choose Investigational Tx
Epocrates researched Rx drug content. Peer-reviewed.
Epocrates Guideline Synopsis Last Update: Oct 23, 2020
Publication Year:
Ab antibody
ACEI angiotensin-converting enzyme inhibitor
ARB angiotensin receptor blocker
AZ azithromycin
CI confidence interval
COVID-19 coronavirus dz 2019
CS corticosteroid
DRV/c darunavir/cobicistat
EHR electronic health record
FPV favipiravir
HCQ hydroxychloroquine
HCW health care worker(s)
IFN interferon
LMWH low-molecular-weight heparin
LOS length of stay
LPV/r lopinavir/ritonavir
NC nasal cannula
NO nitric oxide
NTZ nitazoxanide
RA room air
RCT randomized, controlled trial
RDV remdesivir
SOC standard of care
SOFA sequential organ failure assessment
TCZ tocilizumab
TXA tranexamic acid